United Therapeutics Corporation Forecast, price target & analysts
United Therapeutics Corporation Target price 2025 - Analyst rating & recommendation
United Therapeutics Corporation Classifications & Recommendation:
United Therapeutics Corporation Price Target
| Target Price | $510.00 |
| Price | $454.00 |
| Potential |
12.33%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target United Therapeutics Corporation 2026 .
The average United Therapeutics Corporation target price is $510.00.
This is
12.33%
register free of charge
$609.00
34.14%
register free of charge
$406.02
10.57%
register free of charge
|
|
| A rating was issued by 22 analysts: 16 Analysts recommend United Therapeutics Corporation to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the United Therapeutics Corporation stock has an average upside potential 2026 of
12.33%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.88 | 3.27 |
| 23.63% | 13.68% | |
| EBITDA Margin | 52.85% | 51.67% |
| 0.94% | 2.23% | |
| Net Margin | 41.53% | 36.83% |
| 1.84% | 11.33% |
17 Analysts have issued a sales forecast United Therapeutics Corporation 2025 . The average United Therapeutics Corporation sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an United Therapeutics Corporation EBITDA forecast 2025. The average United Therapeutics Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 United Therapeutics Corporation Analysts have issued a net profit forecast 2025. The average United Therapeutics Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 24.64 | 28.08 |
| 24.38% | 13.96% | |
| P/E | 16.17 | |
| EV/Sales | 5.13 |
18 Analysts have issued a United Therapeutics Corporation forecast for earnings per share. The average United Therapeutics Corporation EPS is
This results in the following potential growth metrics and future valuations:
United Therapeutics Corporation...
Current United Therapeutics Corporation Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Sep 29 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Sep 29 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
